Dec. 30 at 4:37 PM
$EQ Daily Digest
Sanofi-Dynavax
$2.2 billion acquisition ignited biotech sector rally, propelling EQ's 23.77% surge.
On December 24, 2025, Sanofi's announcement of acquiring Dynavax Technologies for
$2.2 billion sparked widespread optimism across the biotechnology sector, which had been recovering from earlier 2025 challenges like pricing pressures. The deal highlighted strong demand for innovative biotech assets, particularly in immunology and vaccines—areas overlapping with Equillium's focus on immune modulation therapies. This led to broad sector gains, with EQ riding the momentum as investors sought exposure to undervalued small-cap biotechs. Trading volume spiked, amplifying the intraday move during regular hours, though no company-specific news directly tied to EQ emerged. Available reports confirm the acquisition as the primary trigger, outpacing general market trends on this holiday-shortened session.
